IBB iShares Biotechnology ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 216.40 | Day Range | 214.04 – 216.07 |
| 52-Week Range | 137.64 – 217.12 | Volume | 1.39M |
| Avg Volume | 1.55M | AUM | $10.84B (Aug 27, 2026) |
| Expense Ratio | 0.44% | Yield (TTM) | 0.19% |
| NAV | 216.37 | Premium/Discount | -0.53% indicative |
| Inception | Feb 05, 2001 | Holdings | 247 |
| Issuer | iShares | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 464287556 | ISIN | US4642875565 |
| Management | Not stated in source data | ||
About this ETF
The iShares Biotechnology ETF (IBB) is designed to mirror the investment performance of a specific market index. This index comprises publicly traded stocks from companies operating within the U.S. biotechnology sector.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +15.02% | +27.73% | +22.70% | +28.22% | +57.88% | +19.25% | +4.78% | +8.58% | +7.46% |
| Total return | +15.02% | +27.75% | +22.81% | +28.33% | +58.28% | +19.59% | +5.05% | +8.86% | +7.64% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.44% | Annual cost of a $10,000 investment | $44.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 25, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 250 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | AMGEN INC | AMGN | 8.61% | 2.06M | $916.3M |
| 2 | VERTEX PHARMACEUTICALS | VRTX | 7.99% | 1.55M | $850.7M |
| 3 | GILEAD SCIENCES | GILD | 7.13% | 5.17M | $759.0M |
| 4 | REGENERON PHARMACEUTICALS | REGN | 5.85% | 751.48K | $622.6M |
| 5 | ARGENX SE ADR | ARGX | 3.67% | 386.93K | $391.2M |
| 6 | MODERNA INC | MRNA | 3.53% | 2.71M | $375.8M |
| 7 | NATERA | NTRA | 3.13% | 1.02M | $333.3M |
| 8 | REVOLUTION MEDICINES | RVMD | 2.82% | 1.42M | $300.0M |
| 9 | ILLUMINA INC | ILMN | 2.36% | 1.12M | $250.9M |
| 10 | BIOGEN | BIIB | 2.23% | 1.09M | $237.7M |
| 11 | ALNYLAM PHARMACEUTICALS | ALNY | 2.19% | 990.15K | $233.7M |
| 12 | BEONE MEDICINES AG | ONC | 2.07% | 592.92K | $220.6M |
| 13 | INSMED | INSM | 1.86% | 1.60M | $198.2M |
| 14 | INCYTE CORP | INCY | 1.77% | 1.47M | $188.7M |
| 15 | UNITED THERAPEUTICS | UTHR | 1.47% | 305.62K | $156.7M |
| 16 | ROIVANT SCIENCES LTD | ROIV | 1.31% | 3.85M | $139.8M |
| 17 | GENMAB SPONSORED ADR | GMAB | 1.21% | 3.89M | $128.4M |
| 18 | ASCENDIS PHARMA | ASND | 1.09% | 460.47K | $116.0M |
| 19 | NEUROCRINE BIOSCIENCES | NBIX | 1.06% | 735.71K | $112.6M |
| 20 | MEDPACE HOLDINGS | MEDP | 1.00% | 171.34K | $106.2M |
| 21 | CHARLES RIVER LABORATORIES INTERNA | CRL | 0.99% | 354.45K | $105.8M |
| 22 | BRIDGEBIO PHARMA | BBIO | 0.96% | 1.26M | $102.1M |
| 23 | EXELIXIS INC | EXEL | 0.93% | 1.81M | $99.0M |
| 24 | HALOZYME THERAPEUTICS | HALO | 0.89% | 874.26K | $95.0M |
| 25 | BIOMARIN PHARMACEUTICAL | BMRN | 0.87% | 1.42M | $92.2M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.19% | Paid (last 12 months) | $0.4115 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 15, 2026 | Last payment | $0.0238 (Jun 18, 2026) |
| Growth 1Y | +7.17% | Growth 3Y / 5Y (ann.) | +7.55% / +7.83% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 15, 2026 | Jun 15, 2026 | Jun 18, 2026 | $0.0238 |
| Mar 17, 2026 | Mar 17, 2026 | Mar 20, 2026 | $0.1218 |
| Dec 16, 2025 | Dec 16, 2025 | Dec 19, 2025 | $0.1831 |
| Sep 16, 2025 | Sep 16, 2025 | Sep 19, 2025 | $0.0828 |
| Mar 18, 2025 | Mar 18, 2025 | Mar 21, 2025 | $0.1212 |
| Dec 17, 2024 | Dec 17, 2024 | Dec 20, 2024 | $0.0624 |
| Sep 25, 2024 | Sep 25, 2024 | Sep 30, 2024 | $0.2005 |
| Mar 21, 2024 | Mar 22, 2024 | Mar 27, 2024 | $0.1260 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 27, 2023 | $0.1240 |
| Sep 26, 2023 | Sep 27, 2023 | Oct 02, 2023 | $0.1532 |
| Jun 07, 2023 | Jun 08, 2023 | Jun 13, 2023 | $0.0062 |
| Mar 23, 2023 | Mar 24, 2023 | Mar 29, 2023 | $0.0646 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 21.65% / 20.93% | Sharpe 1Y / 3Y | 2.71 / 0.892 |
| Max drawdown 1Y / 3Y | -9.63% / -24.85% | Sortino 1Y | 4.49 |
| Beta vs S&P 500 (3Y) | 0.8 | Correlation vs S&P 500 (1Y) | 0.437 |
| Downside deviation 1Y | 13.03% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 1.39M | Average volume | 1.55M |
| AUM | $10.84B | Premium/Discount | -0.53% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $214.4M | +2.02% | $10.63B → $10.84B |
| 1 Week | $709.4M | +6.98% | $10.16B → $10.84B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for IBB
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.